Companies’ listing

Co-Investment
Investment date : 28/12/2012
Country : United States
Sector : Healthcare and life sciences
Website : http://www.atipt.com/

ATI is a leading US provider of outpatient rehabilitation therapy services, for episodic injuries, pre/post operative care, injured workers and sports injuries. In 2012, it manages more than 1 million annual patient visits through 2,000 physical therapists.

Mid Cap Buyout
Investment date : 05/11/2012
Country : Italy
Sector : Industrials
Website : http://www.bruniglass.com

Bruni Glass is a European leader in the field of special glass containers for spirits, food, pharmaceutical products and related accessories. Founded in 1974, Bruni Glass has a particular expertise in speciality products, often developed to meet a customer's specific requirements. Bruni’s target markets are Italy and all Western economies, with a particular focus on North America. The Group offers more than 3,000 products, which firmly establishes Bruni as a benchmark business for the industry. In 2011, the Group had a turnover of more than €108 million, with almost 60% of its sales abroad. Further, Bruni has grown by 16% in the last two years.

Mid Cap Buyout
Investment date : 05/11/2012
Country : Italy
Sector : Industrials
Website : http://www.limacorporate.com

Limacorporate is a global leader in the design, production and distribution of orthopaedic devices. Founded by the Lualdi family in 1945, the group has now 600 employers and three production facilities in Italy. In 2011 it had revenues of 117 million euros, 66% of which was generated in markets outside of Italy. The strategic growth plan for Limacorporate SpA is focused on the further international expansion of the Group and on the enlargement of its existing product portfolio.

Co-Investment
Investment date : 01/11/2012
Country : United States
Sector : Industrials
Website : http://www.acteon.com

Acteon is a global provider of engineering services and products to offshore oil operators and contractors in the subsea arena. In 2012, the Group operates 41 facilities in 17 countries and has nearly 2,000 employees. This investment, alongside KKR, will allow the company to extend its developoment in emerging markets, including Brazil and the West African coast, while pursuing external growth.

Exited participation

Private Debt
Investment date : 19/10/2012
Country : France
Sector : Healthcare and life sciences
Website : http://www.ceva.com


Ceva is a veterinary pharmaceutical laboratory which encompasses all the aspects of the animal health business, from development of the products all the way to their sale in most countries worldwide. Ceva gathers a significant expertise in different therapeutic sectors. The group is specialized in all the animal production chain: industrial (poultry, swine), traditional (ruminants) but also pets and horses.

Mid Cap Buyout
Investment date : 17/10/2012
Country : France
Sector : Industrials
Website : http://www.fivesgroup.com

Fives is an industrial engineering group born 200 years ago. It designs and manufactures process equipment, production lines and turnkey plants for the world’s largest industrial companies in the aluminum, steel, glass, automotive, logistics, cement and energy sectors, both in emerging and developed countries.
In 2011, Fives posted sales of €1.27 billion. It currently employs more than 6,100 people in some 30 countries.

Ardian Growth
Investment date : 01/10/2012
Country : France
Sector : Business services
Website : http://www.esker.fr/

Global market leader in paperless solutions of document processes, Esker commercializes software solutions for businesses and on-demand services (SaaS), to automate the processing of all types of document processes, from start to finish

Mid Cap Buyout
Investment date : 21/08/2012
Country : Germany
Sector : Healthcare and life sciences
Website : http://www.riemser.com/

Riemser is a specialty pharmaceutical company, headquartered in Greifswald, Germany. Riemser operates internationally and has a primary focus on the sales, marketing and lifecycle management of pharmaceutical products for niche therapeutic markets with high medical need in the fields of Oncology, Anti-Infectives and Dermatology. In 2011, Riemser generated sales in excess of €100 million.

<<3 4 5 6 7 8>>

Activities

EXPERTISE

Ardian offers a diversified choice of funds covering the full range of asset classes


FIND OUT MORE

Our Awards

**

Ardian’s work is often acknowledged by the private equity industry for its global vision and professionalism.

OUR AWARDS